Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Large Decrease in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the recipient of a large drop in short interest in July. As of July 31st, there was short interest totaling 93,141 shares, a drop of 64.1% from the July 15th total of 259,720 shares. Based on an average daily trading volume, of 88,009 shares, the short-interest ratio is currently 1.1 days. Currently, 0.1% of the shares of the stock are sold short.

Indaptus Therapeutics Trading Up 0.9%

INDP traded up $0.01 on Friday, hitting $1.07. 130,848 shares of the company’s stock were exchanged, compared to its average volume of 114,071. Indaptus Therapeutics has a fifty-two week low of $0.92 and a fifty-two week high of $8.57. The firm has a 50-day moving average price of $2.51 and a 200-day moving average price of $2.21. The stock has a market cap of $121.17 million, a price-to-earnings ratio of -0.17 and a beta of 1.18.

Indaptus Therapeutics (NASDAQ:INDP) last released its earnings results on Thursday, August 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.57) by $1.55.

Analyst Upgrades and Downgrades

INDP has been the subject of several recent analyst reports. Wall Street Zen raised shares of Indaptus Therapeutics to a “hold” rating in a report on Saturday, June 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Indaptus Therapeutics currently has an average rating of “Sell”.

Institutional Trading of Indaptus Therapeutics

An institutional investor recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC bought a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. Institutional investors own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.